Sun.Sep 17, 2023

article thumbnail

Can AI Compose Clinical Documentation? Absolutely, but with Limits.

MedCity News

A recent academic study of the leading LLM AI models’ ability to read and interpret clinical information demonstrates the incredible power of these tools to support healthcare, but concludes that LLMs should be used as “a supplement to existing workflows rather than as a replacement for human expertise.

article thumbnail

Transforming CDMO partnerships through quality

PharmaTech

This whitepaper explores the criteria for defining true quality in a CDMO partnership, including multiple product, process, and relationship variables

52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CMS Is Getting More Serious About Penalizing Hospitals For Price Transparency Noncompliance

MedCity News

CMS has fined two hospitals in September for alleged violations of its price transparency rule. This marks the third month in a row that the agency has issued fines against hospitals for price transparency noncompliance, following a yearslong period of light enforcement.

110
110
article thumbnail

Driving Patient-First Affordability in Seconds, Not Days: Accelerating Time to Therapy

PharmExec

Webinar Date/Time: Thu, Oct 12, 2023 2:00 PM EDT

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

How care orchestration technology improves the perioperative care process

MedCity News

It is no longer a question of whether we should use automation for care orchestration. The technology for intelligent automation of care coordination is available now and can help providers reduce costs, generate revenue, and overcome understaffing.

109
109
article thumbnail

FDA Approves GSK Myelofibrosis Med That Has Edge Over Others in Drug Class

MedCity News

FDA approval of GSK’s Ojjaara in myelofibrosis introduces a new competitor to blockbuster Incyte drug Jakafi. Ojjaara was part of GSK’s $1.9 billion acquisition of Sierra Oncology last year.

FDA 105